l e t t e r s
Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis [1] [2] [3] . We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an extremely high mutation rate of 7.4 ± 1 protein-changing mutations per million base pairs. Therefore, we conducted integrated analyses of the various data sets to identify pathogenetically relevant mutated genes. In all cases, we found evidence for inactivation of TP53 and RB1 and identified recurrent mutations in the CREBBP, EP300 and MLL genes that encode histone modifiers. Furthermore, we observed mutations in PTEN, SLIT2 and EPHA7, as well as focal amplifications of the FGFR1 tyrosine kinase gene. Finally, we detected many of the alterations found in humans in SCLC tumors from Tp53 and Rb1 double knockout mice 4 . Our study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background.
Small-cell lung cancer (~15% of all lung cancer cases) typically occurs in heavy smokers and is characterized by aggressive growth, frequent metastases and early death 1, 2, 5 . Unfortunately, no single molecularly targeted drug has yet shown any clinical activity in SCLC 6 . Genomic analyses have revealed genetically altered therapeutic targets in lung adenocarcinoma [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and in squamous cell lung carcinoma [17] [18] [19] . By contrast, little is known about the molecular events causing SCLC beyond the high prevalence of mutations in TP53 and RB1 (ref. 3) . Systematic genomic analyses in SCLC are challenging because these tumors are rarely treated by surgery, resulting in a lack of suitable fresh-frozen tumor specimens.
We have established a global lung cancer genome research consortium 19 , giving us access to approximately 6,600 surgically resected lung cancer specimens, out of which we retrieved 99 SCLC specimens. We conducted 6.0 SNP array analyses of 63 tumors, exome sequencing of 27 tumors and 2 cell lines, transcriptome sequencing of 15 tumors and genome sequencing of 2 tumors (Supplementary Table 1 ).
We applied a novel algorithm to identify significant broad ( Supplementary Fig. 1a ) and focal ( Fig. 1a and Supplementary Table 2 ) somatic copy-number alterations (SCNAs) and observed almost universal deletions affecting 3p and 13q (containing RB1), frequent gains of 3q and 5p, and losses of 17p (containing TP53) (Supplementary Fig. 1a) . Gains of 3q affected the region containing SOX2, which was recently shown to be focally amplified in squamous cell lung cancer 19, 20 . However, 3q gains in SCLC were less focal Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer l e t t e r s than those in squamous cell lung cancer (Supplementary Fig. 1b) . Focal amplifications affected MYCL1 (5/63 cases) and MYCN (4/63 cases) 21, 22 (Fig. 1a) . A single case harbored a focal amplification of MYC. All MYC family member amplifications (16% of cases) were mutually exclusive, suggesting genetic epistasis [21] [22] [23] . Focal amplifications affected 8p12, including FGFR1 (6% of cases with copy number of ≥3.5; Fig. 1b) , and 19q12, containing CCNE1 (ref. 24) . FISH analyses in 51 independent specimens validated the occurrence of FGFR1 amplifications in SCLC (n = 3, 6%; Fig. 1c ). We and others have recently reported focal FGFR1 amplifications in squamous cell lung cancer; FGF receptor inhibitors are currently being tested in such patients 17, 19, 25 . Thus, FGFR1-amplified SCLC might benefit from FGFR inhibition. The only significant focal deletion involved FHIT 26 (Fig. 1a and Supplementary Table 2) .
Mice with conditional deletion of Rb1 and Tp53 develop SCLC 4,27-31 bearing amplifications of Mycl1, Mycn and Nfib, which were subsequently also found in human SCLC 28 . We analyzed SCNAs in 20 SCLC tumors (15 primary tumors and 5 metastases) from Tp53 and Rb1 conditional double knockout mice 4 to identify alterations shared by both human and mouse tumors. We found significant amplifications of Mycl1, Mycn and Nfib (Fig. 1d) . In the 15 primary tumors (Supplementary Fig. 2 ), Nfib did not reach statistical significance, suggesting that Nfib amplifications occur later in tumor evolution. Although NFIB was not significantly amplified in the human tumors, three samples had copy-number gain at this locus (data not shown). Furthermore, we identified significant amplifications affecting E2f2, a mediator of RB1 function 32 , and deletions of the histone acetyl transferase gene Crebbp in two mouse tumors (Fig. 1d) .
By analyzing the transcriptome sequencing data of 15 human tumors, we next identified and validated 3 chimeric transcripts ( Fig. 1e and Supplementary Table 3) . Two contained a fusion partner that was also mutated, MPRIP-TP53 and CREBBP-RHBDF1 (Fig. 1e) , both of which are predicted to cause loss of function of the genes involved ( Supplementary  Fig. 3a,b) . Similarly, we also found a low genomic rearrangement frequency by reconstruction from paired-end whole-genome sequencing data of two specimens (Fig. 1f) . This low frequency is in accordance with the spectrum of SCNAs in these samples that show almost exclusively chromosome arm-level events (Supplementary Fig. 4a) .
To identify possible differences in the overall genomic architecture between surgically resected (early stage) samples (n = 17) and samples obtained by autopsy (late stage, n = 10), we compared the spectrum of broad SCNAs in these two sets. We computed absolute copy numbers from sequencing data to correct for admixture of non-tumor cells and for ploidy (Supplementary Fig. 4b and Supplementary Note) but found no significant difference between resected and autopsy cases (Fig. 2a) . Furthermore, there was no difference in the total mutation frequency (Fig. 2b) and no segregation between resected and autopsy cases in an analysis of mutated 'driver' genes ( Fig. 2c,d) . We further identified 5 triploid and 2 near-tetraploid cases (n = 29) and found no statistically significant over-representation of samples with ploidy of >2 between resected and autopsy cases (P = 0.15). On average, we observed a ploidy of 2.3, which is in line with previously reported studies based on DNA cytometry 5 . Thus, resected early-stage tumors and late-stage tumors are genomically similar, underscoring the representative nature of our analysis.
Compared to other tumor types in global sequencing studies [33] [34] [35] [36] [37] [38] [39] [40] [41] , SCLC exhibits an extremely high mutation rate of 7. npg l e t t e r s mutations per million basepairs ( Fig. 2b and Supplementary Fig. 5a ). This high mutation rate is likely linked to tobacco carcinogens, reflected by an elevated rate of C:G>A:T transversions compared to the neutral mutation rate observed in evolution ( Supplementary Fig. 5b ) 38, [42] [43] [44] . To identify pathogenetically relevant driver genes in the context of frequent background mutations, we applied several filters, including analyses of a signature of mutational selection and of gene expression ( Fig. 2c and Supplementary Note). In particular, significantly mutated genes showing an expression level lower than 1 FPKM (fraction per kilobase of exon per million fragments mapped) in more than half of the 15 transcriptomes were removed. Using these adjustments, only two genes had q values of ≤0.1: TP53 and RB1 (Fig. 2d) 37 , SCLC 38 , breast cancer (BC) 35 , ovarian cancer (OC) 40 , multiple myeloma (MM) 34 , ovarian clear cell carcinoma (OCC) 36 , prostate cancer (PC) 33 , renal cell cancer (RC) 41 and chronic lymphocytic leukemia (CLL) 39 . (c) Schematic showing the various steps of our integrated analysis and filtering procedures. All candidate driver genes extracted from sequencing were filtered against gene expression data derived from transcription sequencing. SCNAs were identified from SNP arrays, and candidate SCNA regions that were represented by only a single SCLC sample were subsequently removed. (d) Candidate driver genes identified by significance analysis, presence in the COSMIC (Catalogue of Somatic Mutations in Cancer) database, clustered mutations and genes that are also involved in fusion events. The type of each mutation is shown for every sample, including the gene-specific total number of mutated samples.
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Notably, many of the significantly mutated genes were actually not expressed (Supplementary Table 4) , and none of these mutations were called in the transcriptomes. By contrast, all known tumor suppressors showed expression in the upper part of the overall distribution ( Supplementary Fig. 6 ), supporting the use of our strategy for the elimination of 'passenger' mutations. Additional filters included an analysis of regional clustering of mutations in a given gene (defining a mutational hotspot) and integration with orthogonal data sets and databases (Fig. 2c) 47 . As in the analysis of significantly mutated genes, we discarded genes that were enriched for silent mutations. Together, these filters yielded a list of likely driver genes in SCLC: TP53, RB1, PTEN, CREBBP, EP300, SLIT2, MLL, COBL and EPHA7 (Fig. 2d) . SLIT2 showed a pronounced clustering of mutations (5/29 cases). The observed mutation spectrum (two nonsense, one frameshift deletion and two missense; Fig. 3a) together with frequent genomic losses ( Supplementary Fig. 7a ) suggests that SLIT2 may be a novel tumor suppressor gene in SCLC. We sequenced SLIT2 in 26 additional tumors and 34 cell lines and found an overall mutation frequency of 10% (n = 89). Slit proteins are secreted ligands for Robo receptors, which are involved in axon guidance and cellular migration 48, 49 . Supporting the notion of a tumor suppressive function of SLIT2-ROBO1 in the lung, Robo1-knockout mice do not develop normal lungs; surviving mice exhibit bronchial hyperplasia 50 . Accordingly, a tumor suppressive role for SLIT2 has recently been implied in lung cancer cell lines 51 . Furthermore, ROBO1 was recently found to be a specific serum biomarker of SCLC 52 . EPHA7 was recently described as a tumor suppressor gene that is frequently lost in lymphomas 53 . Given the role of EPHA7 in embryonic development and neural tube closure 54 , mutations in this gene may contribute to the invasive phenotype of SCLC.
Mutations in CREBBP and EP300 were significantly clustered around the sequence encoding the histone acetyltransferase (HAT) domain (Fig. 3b) . Of these mutations, those affecting the homologous Asp1399 (EP300) and Asp1435 (CREBBP) residues both affect acetylase activity in vitro [55] [56] [57] . Furthermore, the p.Gly1411Glu alteration in CREBBP has previously been identified in lung cancer 58 and follicular lymphoma 59 , and p.Gly1411Val as well as p.Asp1435Gly were found in relapsed acute lymphoblastic leukemia 60 , suggesting a mutational hotspot. By contrast, the p.Arg386fs alteration and the CREBBP-RHBDF1 gene fusion truncate the protein at the N terminus ( Fig. 3c and Supplementary Fig. 3a) . Together with the observation of Crebbp deletions in mouse SCLC (Fig. 1d) and the recently described CREBBP-BTBD12 gene fusion in the NCI-H209 SCLC cell line 38 , inactivation of CREBBP and EP300 likely has a major role in SCLC. Focused sequencing of the HAT domain-encoding exons of CREBBP and EP300 in a validation set of 26 additional SCLC tumor specimens and 45 cell lines, as well as break-apart FISH performed in 34 SCLC cell lines, confirmed an overall mutation frequency of 18% (point mutations, insertions and/or deletions (indels) and gene rearrangements) (Fig. 3b-d) . CREBBP and EP300 mutations have recently been described in relapsed acute lymphoblastic leukemia and B-cell lymphoma 57, 61 but have not been observed at such high frequency in solid tumors to date. Furthermore, all mutations and most of the deletions in CREBBP and EP300 occurred in a mutually exclusive fashion in the total set of 101 samples analyzed, suggesting epistasis (Fig. 3e) . The observed alterations are predominantly heterozygous, supporting haploinsufficiency 57, 62 . Thus, even hemizygous deletions occurring in at least 10% of non-mutant samples ( Fig. 3e and Supplementary  Fig. 7b ) may be considered inactivating.
Further supporting the relevance of CREBBP and EP300 mutations in SCLC, all but one (the mutation encoding the p.Asn1286Ser alteration in EP300) of the missense mutations were classified as being damaging by computational analyses 63 . Furthermore, all HAT domain alterations were located at the interface of substrate binding 56 ( Fig. 4a) , thus supporting the notion that they may affect catalytic activity. We assessed the functional impact on histone acetylation of npg l e t t e r s the p.Gly1411Arg, p.Asp1435Tyr and p.Ser1432Pro CREBBP alterations (homologous to p.Gly1375Arg, p.Asp1399Tyr and p.Ser1396Pro alterations in EP300) in reconstitution experiments in Crebbp fl/fl ; Ep300 fl/fl (Crebbp and Ep300 Cre-deleted double knockout) mouse embryonic fibroblasts (MEFs) [64] [65] [66] . All three mutations significantly reduced acetylation of histone 3 lysine 18 (H3K18) (Fig. 4b,c) . Specifically, p.Asp1435Tyr induced complete, p.Gly1411Arg pronounced and p.Ser1432Tyr moderate loss of H3K18 acetylation. Furthermore, knockdown of CREBBP in the DMS114 SCLC cell line that lacks CREBBP HAT domain alterations resulted in a moderate but significant increase in cell proliferation (Fig. 4d,e) . Tumors with mutations and hemizygous deletions in CREBBP and EP300 did not exhibit a significantly different pattern of gene expression compared to wild-type tumors after correcting for multiple hypothesis testing (data not shown), suggesting that global changes in gene expression are not the predominant mechanism by which loss of HAT activity contributes to SCLC pathogenesis. Taken together, these results support a role for loss of CREBBP and EP300 function in the biology of SCLC. Another histone-modifying enzyme mutated in SCLC was the methyltransferase gene MLL, which was recurrently mutated to alter Ile960 (p.Ile960Met) 47 . MLL rearrangements occur in acute leukemia 67, 68 . Similarly, recurrent genetic alterations in histone modifying genes seem to be a newly identified hallmark of SCLC.
Confirming previous reports 69 , we found mutations in PTEN (3/29 cases), all of which are likely (p.Gly165Glu) or proven (p.His61Arg and p.Arg130Gly) to affect phosphatase activity 70 , thereby activating the phosphatidylinositol 3-kinase (PI3K) pathway. We did not observe any mutations in PIK3CA 71 .
We developed a mathematical model that gives insight into the allelic state of each tumor and yields estimates of tumor heterogeneity (Supplementary Note). On average, we observed a rather low heterogeneity of approximately 6.5% (Supplementary Table 5 ). Using the reconstructed allelic states of each tumor, we found that copy-neutral loss of heterozygosity (CNLOH) events (complete loss of one allele at a given locus combined with a match of the absolute copy number at that locus with the overall ploidy of the sample) were enriched at the TP53 and RB1 loci (Fig. 5a,b) . Furthermore, all TP53 and RB1 mutations in CNLOH regions were early events (Fig. 5b) , as their allelic fractions were compatible with the tumor purity. By integrating the different data sets, we found that at least one allele of TP53 and RB1 was affected by any genomic event (mutation (including rearrangement) or hemizygous deletion (LOH)) in all cases (Fig. 5c) . Thus, similar to genetically manipulated mouse models of SCLC, inactivation of TP53 and RB1 are early and necessary events in the development of SCLC in humans as well 4, [27] [28] [29] [30] [31] . Finally, we identified one case, in which the affected individual had undergone surgery for lung adenocarcinoma 3 years before diagnosis with SCLC. Whereas both tumors contained the same TP53 alteration (p.Val73fs), the RB1 alteration (p.Arg251*) was restricted to the SCLC tumor (Supplementary Fig. 8 ), compatible with trans-differentiation of adenocarcinoma cells to SCLC cells, mediated in part through loss of RB1. Acquired resistance of EGFR-mutant lung adenocarcinomas to EGFR inhibition has been linked with trans-differentiation to SCLC 72, 73 . It is tempting to speculate that loss of RB1 may be mechanistically involved in such cases of acquired resistance as well.
Despite methodological challenges (limited sample set and high mutation frequency), integrative genome analyses of human and mouse SCLCs afforded a molecular map of this tumor type, condensed in five categories (Fig. 5d) . The tumor-suppressive functions of p53 rely on its acetylation by CREBBP or EP300 (refs. [74] [75] [76] [77] [78] [79] . However, given the universal loss of p53 function in SCLC, the tumor suppressive functions of CREBBP that we observed are likely independent of p53. One of the best-studied functions of SLIT2 is its involvement in actin polymerization mediated by Cdc42 (ref. 80) . We speculate that this property might enhance invasive capabilities and thus contribute to the aggressiveness of SCLC. The reported functions of EPHA7 (refs. 53,54) may also contribute to this phenotype. Beyond universal losses of TP53 and RB1 and amplifications of MYCL1, MYCN and MYC, we present PTEN mutations and FGFR1 amplifications as potentially therapeutically tractable genome alterations. Finally, we define genomic alterations that affect the histone-modifying enzymes CREBBP, EP300 and MLL as the second most frequently mutated class of genes in SCLC. In summary, our study represents a npg l e t t e r s considerable extension of the current molecular concept of SCLC and, more broadly, provides an example of how integrative computational genome analyses can provide functionally tractable information in the context of a highly mutated cancer genome.
URLs. ATCC, http://www.atcc.org/.
MeThOdS
Methods and any associated references are available in the online version of the paper.
Accession codes. Binary sequence alignment data of 300-bp regions around all identified somatic mutations, segmented human SNP array data and segmented mouse aCGH data can be downloaded from http://www.uni-koeln.de/sclc/SCLC_Data.tgz. 
Note: Supplementary information is available in the online version of the paper.
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ONLINe MeThOdS
Sample preparation, DNA and RNA extraction and Illumina sequencing. Total RNA and DNA were obtained from fresh-frozen tumor and matched fresh-frozen normal tissue or blood. Tissue was frozen within 30 min after surgery and was stored at -80 °C. For autopsy cases, tumors were derived within a few hours after death. Blood was collected in tubes containing the anticoagulant EDTA and was stored at −80 °C. Total DNA and RNA were extracted from fresh-frozen lung tumor tissue containing more than 60% tumor cells. Depending on the size of the tissue, 15-30 sections, each 20 µm thick, were cut using a cryostat (Leica) at -20 °C. The matched normal sample obtained from frozen tissue was treated accordingly. DNA from sections and blood was extracted using the Puregene Extraction kit (Qiagen) according to the manufacturer's instructions. DNA was eluted in 1× TE buffer (Qiagen), diluted to a working concentration of 150 ng/µl and stored at -80 °C.
We used the SPRIworks system (Beckman Coulter) for automated library construction. For whole-exome sequencing, exome enrichment was performed using the SureSelect Human All Exon 38Mbp Kit (Agilent), following the manufacturer's protocol. Exon-enriched libraries were subsequently paired-end sequenced using mostly a read length of 2 × 95 bp on the Illumina Genome Analyzer IIx (Supplementary Table 5 ). Whole-genome sequencing was performed on the Illumina HiSeq 2000 using a read length of 2 × 100 bp for all samples.
Sections for RNA extraction were disrupted and homogenized for 2 min at 20 Hz with the Tissue Lyser (Qiagen), and RNA was extracted using the Qiagen RNeasy Mini kit. RNA quality was assessed in a Bioanalyzer, and only samples showing an RNA integrity number (RIN) of >8 were retained for transcriptome sequencing. RNA sequencing (RNA-seq) was performed on cDNA libraries prepared from PolyA + RNA extracted from tumor cells. We aimed for a library with an insert size of 250 bp, allowing us to sequence 95-bp paired-end reads without overlap. All RNA-seq libraries were sequenced on the Illumina Genome Analyzer IIx.
Processing of whole-exome and whole-genome sequencing data. Raw sequencing data were aligned to the human genome (NCBI Build 36/hg18) using MAQ 82 (version: 0.7.1) for whole-exome data and the Burrows-Wheeler Aligner (BWA; version: 0.5.9rc1) 83 for whole-genome sequencing data. To prevent miscalls that might be caused by duplicated sequencing errors, possible PCR duplicates were removed form the alignments. The quality of the sequencing data was assessed by evaluating criteria such as on-target coverage (exome), average coverage and insert size. These quality metrics are summarized in Supplementary Table 5. Mutation detection. We implemented a new variant caller to identify somatic mutations from the aligned sequencing (M.P. et al., unpublished data). To this end, tumor-specific characteristics, including local SCNAs, tumor purity, and total aneuploidy were incorporated into a mathematical model that controls variant calling. Details of our approach are presented in the Supplementary Note.
Reconstruction of rearrangements from whole-genome paired-end data. To reconstruct rearrangements from paired-end data, we first screened for read pairs that were either separated by at least 600 bp or showed incorrect orientation. For the regions encompassing this type of read pair, we next examined whether the region had aberrant reorganization in the matched normal sample. The remaining genomic locations were then annotated for repetitive elements. We discarded those locations where both pairs mapped to the same repeat type, as the sequences showed a very high degree of homology, which might lead to an elevated rate for the alignment of artifacts. The remaining candidates were finally filtered by comparing the coverage of the read pairs to the total read coverage in the region that encompassed the reads. To validate these candidates by genomic PCR, two candidate-specific primer sets encompassing the fusion points were designed: one for each of the two possible orientations of the rearrangements. All validated genomic rearrangements are shown in Supplementary Fig. 9 and Supplementary Table 6 .
Validation of somatic mutations and frequently mutated genes. Because of the high mutation rate, we only systematically validated by dideoxy sequencing those mutations that were detected in the candidate driver genes TP53, RB1, PTEN, CREBBP, EP300, SLIT2, MLL, COBL and EPHA7. For CREBBP, EP300 and SLIT2, we extended our sequencing efforts to an independent validation cohort. To this end, we sequenced the regions around the gene sequence encoding the HAT domain (exons [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] for CREBBP and EP300 by dideoxy sequencing. For SLIT2, the full-length gene was screened for mutations using 454 sequencing. Further details and results from our validation strategy are given in the Supplementary Note. Analysis of significantly mutated genes and detection of mutational hotspots within a gene. The analysis of significantly mutated genes was an extension of a previously described method 84 to correct for gene expression and the accumulation of synonymous mutations. Conceptual and mathematical details are outlined in the Supplementary Note.
Mutational hotspots within a gene were detected by resampling positions of observed mutations. P values were computed by comparing the observed variance of the mutations with the distribution of the variance derived from resampled mutations. We restricted this analysis to genes with at least three somatic mutations and those that did not show enrichment of silent mutations; frameshift indels were not considered. The results of this analysis for all genes having a P value of ≤0.05 are shown in Supplementary Table 7 .
Analysis of RNA-seq data. For analysis of RNA-seq data, we have developed a pipeline that affords accurate and efficient mapping and downstream analysis of transcribed genes in cancer samples (R. Sun et al., unpublished data). Details of this method are presented in the Supplementary Note.
FISH analyses.
A dual-color break-apart FISH assay was developed to assess CREBBP and EP300 (chromosomes 16 and 22, respectively) rearrangements on the chromosomal level, as has been described previously 85 . For the CREBBP break-apart assay, we used the BAC clone RP11-962J17 for centromeric labeling with digoxigenin (green) and RP11-363A1 for telomeric labeling with biotin (red). Similarly, for the EP300 break-apart assay, we used BAC clone RP11-928B9 for telomeric labeling with digoxigenin (green) and RP11-844C16 for centromeric labeling with biotin (red). Further information about the break-apart FISH assay is given in the Supplementary Note. FGFR1 FISH analysis was carried out as described elsewhere 86 .
Analysis of SNP 6.0 data. Genomic DNA was hybridized to Affymetrix SNP 6.0 arrays according to the manufacturer's instructions. Raw signal intensities were processed using the same approach as in a previous publication 19 , with modifications in the normalization of SNP probes. Allele-specific copy numbers were estimated using an adaption of the PLASQ algorithm 87 to the design of the SNP 6.0 arrays. Parameters of the log linear model that account for allele-specific probe affinities and probe-specific background were calibrated by a Gauss-Newton approach. The resulting raw copy numbers were segmented using circular binary segmentation 88 . Significantly amplified and deleted regions were assessed by a novel rank sum-based method (Supplementary Note). aCGH analysis of mouse tumors. We extracted tumor and normal DNA form explanted p53-and Rb1-deficient SCLC mouse tumors using the Gentra DNA extraction kit (Qiagen, Gentra Puregene). In total, 20 tumors were analyzed. Among the 20 tumors, we analyzed 15 primary tumors and 5 tumors at metastatic sites. Of the five metastases, two tumors were harvested from an independent mouse, whereas the remaining three were explanted from the same mouse from which a primary tumor had been extracted. Arrays were hybridized and analyzed as described previously 4 .
Analysis of histone acetylation by indirect immunofluorescence.
MEFs with conditional alleles of Crebbp and Ep300 were transduced with retrovirus expressing HA-tagged Crebbp protein (either with or without alterations in the HAT domain). After retroviral transduction, the endogenous loxP-flanked (floxed) alleles of Crebbp and Ep300 were recombined using Cre-expressing adenovirus to produce MEFs lacking endogenous Crebbp and Ep300 (double knockout MEFs). Four days after deletion of endogenous Crebbp and Ep300, cells were seeded on slides. The following morning, cells were fixed (in 3% paraformaldehyde for 10 min at room temperature), permeabilized (0.1% Triton X-100 in PBS) and blocked in 3% nonfat milk in PBS for 30 min. Cells were incubated with primary antibody against the HA tag (1:500 dilution; mouse monoclonal HA-11, Covance) or H3K18Ac (1:1,000 dilution; rabbit polyclonal ab1191, Abcam) for 3 h at room temperature, and cells were then washed and incubated with secondary antibody (1:500 dilution; donkey antibody to mouse conjugated to CY3, Jackson or 1:500 dilution; goat antibody to rabbit conjugated to Alexa Fluor 488, Invitrogen) and DAPI for 1 h. Confocal images were acquired, and individual nuclei were masked on the basis of the DAPI signal. The mean signal intensity for the nuclei was assessed using Slidebook software. The background mean signal intensities for HA (CY3) and H3K18Ac (Alexa 488) were determined for nuclei from double knockout MEFs not transduced with retrovirus. Data were expressed as the ratio of the mean H3K18Ac signal intensity for each nucleus to the mean HA signal intensity for the same nucleus. Background signal was subtracted from each mean signal intensity value before the ratio was calculated. Only nuclei with a Crebbp-HA mean signal intensity that was at least twofold above background were analyzed. Graphs and statistics were produced using Prism GraphPad software. The immunofluorescence protocol (with some modifications) was described previously 29, 66 .
CREBBP knockdown and growth analysis. Cell lines: The SCLC cell line DMS114 was cultivated in RPMI medium (Sigma Aldrich) supplemented with 10% FCS (PAA Laboratories) and 1% penicillin-streptomycin (Invitrogen). The cell line was confirmed to be free of cross-contaminations based on a short tandem repeat (STR) analysis conducted at the Leibniz-Institute DSMZ. The DMS114 cell line lacks CREBBP mutations and deletions, as determined by cDNA sequencing and copy-number analysis, respectively.
shRNA-mediated knockdown of CREBBP in DMS114: A CREBBP-specific shRNA (AAATGCCAGTGACAAGCGAAACCAACAAA, OriGENE) and a scrambled shRNA control sequence (AACAAGATGAAGAGCACCAA, Sigma-Aldrich) were inserted into a pLKO.1-puro-based vector (Sigma) and cotransfected with pMD.2 and pCMVd.8.9 helper plasmids into HEK 293 TL cells using the TransIT-LT1 reagent (Mirius). Similarly, pLKO.1-puro vectors without any shRNA inserts were applied and served as an additional control. After 48 h, replication-incompetent lentiviruses were collected from the supernatant to infect DMS114 cells in the presence of 10 µg/ml polybrene (Millipore). To select for transduced cell clones, medium was replenished with growth medium containing 3 µg/ml puromycin (Sigma) 24 h after infection.
Protein blot analysis: Equal protein amounts of cellular lysates were separated on 4-12% Tris-glycine gels (Invitrogen) and subjected to protein blot analysis to detect endogenous amounts of CREBBP (A-22, SC-369, Santa Cruz Biotechnology) and actin (691001, MP Biomedicals).
Cell growth analysis: Virally transduced DMS114 cells were seeded into 6-well dishes (50,000 cells per well) and maintained for 5 d in selective growth medium. Cell growth was assessed by counting the cellular particles (Z1 Particle Counter, Beckman Coulter) in triplicate every 1-2 d.
Cell culture. Cell lines were obtained in part from the American Type Culture Collection (ATCC) or were received as a kind gift from X.X. Ninomiya (University Hospital Okayama) and were cultured as described previously 89 , using either RPMI or HITES cell culture medium supplemented with 10-20% FBS. Whole-genome DNA was extracted from cell lines using the Puregene kit (Qiagen) as described previously 89 .
Dideoxy sequencing. For validation sequencing, primer pairs were designed to enclose the putative mutation. For resequencing, we designed primer pairs that covered the desired amplicons. Sequencing was carried out as described previously 90 , and electropherograms were analyzed by visual inspection using Mutation Surveyor 2.03 software (SoftGenetics).
Additional data are given in Supplementary Figures 10-12 
